EcoDrugPlus

Fibroblast Growth Factor Receptor 1-A-Like

Ensembl ID : ENSSTUG00000016883
Gene Symbol: LOC115200093
3 Cross references
203 Possible Orthologues:

Fibroblast Growth Factor Receptor 2-Like

Ensembl ID : ENSSTUG00000014734
Gene Symbol: LOC115162870
3 Cross references
213 Possible Orthologues:

Fibroblast Growth Factor Receptor 2-Like

Ensembl ID : ENSSTUG00000044836
Gene Symbol: LOC115194075
3 Cross references
213 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSSTUG00000011565
Gene Symbol: FGFR3
3 Cross references
191 Possible Orthologues:

Fibroblast Growth Factor Receptor 3-Like

Ensembl ID : ENSSTUG00000023361
Gene Symbol: LOC115183113
3 Cross references
188 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSSTUG00000012900
Gene Symbol: FLT1
2 Cross references
192 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSSTUG00000043943
Gene Symbol: FLT1
1 Cross references
192 Possible Orthologues:

Folate Receptor Alpha-Like

Ensembl ID : ENSSTUG00000018891
Gene Symbol: LOC115206595
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSSTUG00000039225
Gene Symbol: LOC115177101
2 Cross references
332 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSSTUG00000039232
Gene Symbol: LOC115176983
2 Cross references
300 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSSTUG00000035100
Gene Symbol: LOC115177177
2 Cross references
299 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSSTUG00000035103
Gene Symbol: LOC115177185
2 Cross references
331 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).